2026-06-16T08:51:15Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/88052024-03-13T01:05:21Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220

2024-03-12T10:53:35Z urn:hdl:10259/8805 Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson’s Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up Santos García, Diego Deus-Fonticoba, Teresa de Cores Bartolomé, Carlos Canfield, Héctor Paz González, José Manuel Martínez Miró, Cristina Valdés Aymerich, Lorena Suárez Castro, Ester Jesús, Silvia Aguilar, Miquel Pastor, Pau Planellás, Lluis L. Cosgaya, Marina García Caldentey, Juan Caballol, Núria Legarda, Inés Hernández Vara, Jorge Cabo López, Iria López Manzanares, Lydia González Aramburu, Isabel Ávila Rivera, María A. Catalán, María José Nogueira, Víctor Puente, Víctor Dotor, Julio Borrue, Carmen Solano, Berta Álvarez Saúco, María Vela Desojo, Lydia Escalante Arroyo, Sonia Cubo Delgado, Esther Carrillo Padilla, Francisco Martínez Castrillo, Juan Carlos Sánchez Alonso, Pilar Alonso Losada, María Gema López Ariztegui, Nuria Gastón, Itziar Kulisevsky Bojarsky, Jaume Blázquez Estrada, Marta Seijo, Manuel Ruíz Martínez, Javier Valero, Caridad Kurtis, Mónica M. Fabregues, Oriol de González Ardura, Jessica Alonso Redondo, Rubén Ordás Bandera, Carlos Manuel López Díaz, Luis M. McAfee, Darrian Martínez Martín, Pablo Mir, Pablo COPPADIS Study Group Mood Non-motor symptoms Parkinson’s disease Progression Quality of life Background and Objective: Non-motor symptoms (NMS) progress in different ways between Parkinson’s disease (PD) patients. The aim of the present study was to (1) analyze the change in global NMS burden in a PD cohort after a 2-year follow-up, (2) to compare the changes with a control group, and (3) to identify predictors of global NMS burden progression in the PD group. Material and Methods: PD patients and controls, recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017, were followed-up with after 2 years. The Non-Motor Symptoms Scale (NMSS) was administered at baseline (V0) and at 24 months ± 1 month (V2). Linear regression models were used for determining predictive factors of global NMS burden progression (NMSS total score change from V0 to V2 as dependent variable). Results: After the 2-year follow-up, the mean NMS burden (NMSS total score) significantly increased in PD patients by 18.8% (from 45.08 ± 37.62 to 53.55 ± 42.28; p < 0.0001; N = 501; 60.2% males, mean age 62.59 ± 8.91) compared to no change observed in controls (from 14.74 ± 18.72 to 14.65 ± 21.82; p = 0.428; N = 122; 49.5% males, mean age 60.99 ± 8.32) (p < 0.0001). NMSS total score at baseline (β = −0.52), change from V0 to V2 in PDSS (Parkinson’s Disease Sleep Scale) (β = −0.34), and change from V0 to V2 in NPI (Neuropsychiatric Inventory) (β = 0.25) provided the highest contributions to the model (adjusted R-squared 0.41; Durbin-Watson test = 1.865). Conclusions: Global NMS burden demonstrates short-term progression in PD patients but not in controls and identifies worsening sleep problems and neuropsychiatric symptoms as significant independent predictors of this NMS progression. 2024-03-12T10:53:35Z 2024-03-12T10:53:35Z 2021-06 info:eu-repo/semantics/article http://hdl.handle.net/10259/8805 10.3390/jpm11070626 2075-4426 eng Journal of Personalized Medicine. 2021, V. 11, n. 7, 626 https://doi.org/10.3390/jpm11070626 http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Atribución 4.0 Internacional MDPI